Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-10 09:43 am Unchanged |
2022-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR |
Flynn James E | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2022-11-09 4:43 pm Sale |
2022-10-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR |
BlackRock Inc. BLK |
0 0.000% |
-900,132 (Position Closed) |
Filing |
| 2022-02-14 2:34 pm Purchase |
2021-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCRU |
T. Rowe Price Associates, Inc. | 730,864 5.400% |
730,864 (New Position) |
Filing History |
| 2022-02-08 5:12 pm Sale |
2021-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR |
BlackRock Inc. BLK |
900,132 6.700% |
-24,868 (-2.69%) |
Filing |
| 2021-02-12 4:02 pm Purchase |
2020-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR |
Eucrates LLC | 2,619,906 19.500% |
2,619,906 (New Position) |
Filing History |
| 2021-02-05 5:51 pm Purchase |
2020-12-31 | 13G | Eucrates Biomedical Acquisition Corp. EUCR |
BlackRock Inc. BLK |
925,000 6.900% |
925,000 (New Position) |
Filing |
| 2020-10-30 11:39 am Purchase |
2020-10-27 | 13G | Eucrates Biomedical Acquisition Corp. EUCRU |
Flynn James E | 1,000,000 7.780% |
1,000,000 (New Position) |
Filing History |